ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

NCI Offers Chlorozotocin

November 18, 1977

HHS Approves Six State Plans To Insure Women With Cancer

June 8, 2001

Utah, Hopkins Get Large Donations To Support Research

October 6, 1995

Declining Support Among Oncologists For Euthanasia.

October 13, 2000

In Brief: Streamlining Of Contract Award Process Still Top Priority At NCI; Training Grants No Closer

January 10, 1975

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

June 29, 2012